MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech disciplines, including drug delivery, wound management, urology, and diabetes care. MediPhorum’s mission is to better connect MedTech organizations to create industry-led solutions to its shared challenges.
The current compendial sterility test has a 14-day incubation time and is often the time-limiting step in the ‘assess and release’ process of pharmaceutical products. There is an ever-increasing number of alternative sterility test systems available that have benefits in addition to faster time-to-result, such as standardization and automation of readouts (eliminating analyst subjectivity) and improved data integrity (e.g., eliminating the need...
The absence of adventitious agents must be demonstrated to release biotherapeutics. Yet, the traditional compendial methods that have been used for decades for this purpose are laborious, difficult to automate, time-consuming, have a long analytical lead time, and can cause significant delays before results are obtained. Alternative adventitious agent detection methods, or adventitious agent tests (AATs), have been available for many years and...
The biopharmaceutical industry is undergoing rapid growth and is challenged to deliver multi-modality products to a patient-centric global market. However, this requires a significant transformation in strategy, technology, R&D, and manufacturing. This is where BioPhorum Technology Strategy will play a leading role. BioPhorum Technology Strategy is the new name for BioPhorum Technology Roadmapping, which originated in 2015 from the need to...
Analytical instrument vendors have been integral to developing and publishing our technology roadmaps and developing product monitoring requirements and proof-of-concept activities. As the biomanufacturing community moves to adopt recommendations in BioPhorum’s Technology Roadmapping roadmap vision, senior leaders recognize that including vendor partners in extended programs will greatly improve the integrity,...
As technologies become available that allow us to better monitor and understand manufacturing processes, quality professionals will be able to make decisions more quickly, so lead times will shorten. As analytical testing moves from the traditional quality control (QC) laboratory to the production floor, one of the challenges is how to ensure the required independence of QC from production. However, current good manufacturing practice (GMP)...
Industry research indicates that using smart maintenance could mean manufacturers and suppliers in the chemical and pharmaceutical industries gain 5–15% in plant up-time and reduce maintenance costs by 18–25%. Reports also suggest a 5–20% downtime reduction and a 10–40% maintenance cost reduction. Yet, while predictive maintenance technology is already advancing in the chemical industry, especially with retrofit solutions in aging continuous...
There is a common misunderstanding that 100% visual inspection (VI) of biopharmaceutical products should mean 100% detection of defects. This idea is repeated across geographies and arises within companies and externally (e.g., during internal audits and regulatory reviews). Yet if you routinely work in VI, you know the process is inherently probabilistic and so, despite all units of a product undergoing full VI, identifying all defects is not...
Have your outbound supply chain costs increased? Do you want to leverage data and digital technologies more effectively to reduce complexity and risk in your outbound supply chain? Want to be instrumental in developing the biopharmaceutical supply chain of the future? Well, now you can, by being part of BioPhorum Supply Chain to Patient. The complex nature and multiple challenges of the outbound supply chain make meaningful changes across the...
A user requirement specification (URS) for equipment, facilities, utilities and systems should define all the requirements needed to create a feasible design to meet a system’s purpose. It should ensure that essential quality elements are built-in and any risks to good manufacturing practice, product quality, and patient safety are mitigated. Success relies on a clear, shared, industry-wide understanding of definitions and requirements.
Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.
We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C>-specific validation issues, as well as working toward resolving the current challenges to commercializing C> products. Discover more and learn about the outputs here.
The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.
Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives
Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.
Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.
Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges. To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here.Â
IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum.Â
The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation.Â
BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, Filing and Review, Interactions with Health Authorities, and Harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.
The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.
BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:
There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.
The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.
BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.
With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.
This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.
The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.
Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.
AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.
Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.
